key: cord-0885151-vuye4a1z authors: Nordan, Taylor; Couper, Gregory S.; Chen, Frederick Y.; Vest, Amanda; DeNofrio, David; Kawabori, Masashi title: Patterns of Use of Temporary Mechanical Circulatory Support as a Bridge to Transplant During the Coronavirus Disease 2019 (COVID-19) Pandemic date: 2020-09-11 journal: J Card Fail DOI: 10.1016/j.cardfail.2020.09.004 sha: d99dd6f7240923febd7b74a6e1964202f4b77421 doc_id: 885151 cord_uid: vuye4a1z nan Since implementation of the new donor heart allocation system in October 2018, the proportion of patients bridged with temporary mechanical circulatory support (MCS) has increased drastically. 1 In particular, utilization of extracorporeal membrane oxygenation (ECMO) and intraaortic balloon pump (IABP) as a bridge to transplant (BTT) has nearly quadrupled. However, in January 2020, the first case of coronavirus disease 2019 (COVID-19) was reported in the United States and has since given rise to an unprecedented pandemic. 2 Notably, this pandemic has had a substantial impact on all aspects of heart transplantation, 3 with use of active waitlist status for those in most dire condition. We sought to elucidate temporal patterns of ECMO and IABP use as a BTT following implementation of the new donor heart allocation system and the emergence of the COVID-19 pandemic. The United Network for Organ Sharing (UNOS) database was queried for all adult single-organ first-time heart transplants occurring between January 2014 and May 2020. Interrupted time series analysis was performed to evaluate trends concerning ECMO and IABP as a BTT. ECMO and IABP were considered a BTT if the recipient was supported by the device at the time of transplant. Four time periods were defined as: 1) the system prior to publication of the new system in August 2016 (n=5673); 2) publication of the new system prior to implementation in October 2018 (n=5407); 3) implementation of the new system prior to appearance of COVID-19 in January 2020 (n=3097); and 4) COVID-19 (n=880). Months with significant events were included as transition periods. This study was deemed exempt from institutional review board review since the UNOS database is publicly available and contains deidentified data. Analysis was performed using the Stata version 16 (College Station, TX) ITSA command to quantify the effect of significant events on the percentage of patients bridged to transplant with ECMO and IABP. 4 A p-value <0.05 was considered statistically significant. The percentage of patients bridged with ECMO increased from 4.42% in November 2018 to 5.94% in December 2019, while the percentage decreased from 3.39% in February 2020 to 1.92% in May 2020. Before publication of the new allocation system, the percentage of patients bridged with ECMO was increasing at 0.02% per month (95% CI: -0.003% to 0.04%, p=0.082) with minimal decrease in slope of 0.001% per month (95% CI: -0.03% to 0.03%, p=0.963) following publication. The slope increased significantly by 0.24% per month (95% CI: 0.08% to 0.41%, p=0.004) following implementation compared to the publication period. After the beginning of the COVID-19 pandemic, the slope decreased by 0.62% per month (95% CI: -0.72% to -0.51%, p<0.001) ( Figure A) . The percentage of patients bridged with IABP increased from 21.0% in November 2018 to 31.5% in December 2019, while the percentage decreased from 33.1% in February 2020 to 11.5% in May 2020. Prior to publication of the new allocation system, the percentage of patients supported by IABP was increasing at 0.04% per month (95% CI: -0.03% to 0.11%, p=0.234) followed by a slight decrease in slope of 0.06% per month (95% CI: -0.19% to 0.06%, p=0.302) after new allocation system publication. The slope increased significantly following implementation of the new system by 1.15% per month (95% CI: 0.58% to 1.71%, p<0.001) compared to the period after publication. The slope decreased significantly by 5.85% per month (95% CI: -7.14% to -4.55%, p<0.001) following the beginning of the COVID-19 pandemic ( Figure B ). While the percentage of patients bridged with ECMO and IABP increased as expected following implementation of the new allocation system, these trends have reversed sharply following emergence of the COVID-19 pandemic. The change we observe during the COVID-19 pandemic may be reflective of intensive care unit space and resource diversion toward care of COVID-19 patients as opposed to those supported by temporary MCS, limited access to rapid COVID-19 testing for those supported by temporary MCS, and patient apprehension surrounding hospital visits during the COVID-19 pandemic, reflected by decreased rates of heart failure hospitalization with potential increase in waitlist mortality 5, 6 We expect bridging patterns to normalize following loosening of COVID-19 restrictions in line with heart failure hospitalization rates. 7 . This study contains limitations inherent to a retrospective analysis. Patterns of ECMO and IABP use in potential recipients who were listed with these devices but did not make it to transplant remain unknown. In addition, the COVID-19 pandemic has had an unequal impact on varying regions of the country, which is not reflected in this study. Reassessing Recipient Mortality Under the New Heart Allocation System: An Updated UNOS Registry Analysis First Case of 2019 Novel Coronavirus in the United States Trends in US Heart Transplant Waitlist Activity and Volume During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Cardiol Conducting Interrupted Time-Series Analysis for Single-and Multiple-Group Comparisons Pandemic on Use of Emergency Departments for Acute Life-Threatening Conditions -United States Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic Lifting COVID-19 Shelter-in-Place Restrictions: Impact on Heart Failure Hospitalizations in Northeast Georgia The monthly change in percentage of patients transplanted is displayed under the time period denoted -old system‖, followed by the change in monthly percentage (-slope‖) relative to the antecedent period for time periods denoted -New System Published‖ Abbreviations: ECMO, extracorporeal membrane oxygenation COVID-19, coronavirus disease None. The authors have nothing to declare.